An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5385-5389

  You, Liang ^a   He, Biao ^a   Xu, Zhidong ^a   Uematsu, Kazutsugu ^a   Mazieres, Julien ^a   Fujii, Naoaki ^b   Mikami, Iwao ^a   Reguart, Noemi ^a   McIntosh, Joe K ^a   Kashani Sabet, Mohammed ^a   McCormick, Frank ^a   Jablons, David M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; SURVIVAL FACTOR; SURVIVIN; UNCLASSIFIED DRUG; WNT 2 MONOCLONAL ANTIBODY; WNT PROTEIN; WNT2 PROTEIN;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DISHEVELLED GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MODEL; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BETA CATENIN; CYTOSKELETAL PROTEINS; DOWN-REGULATION; HUMANS; LIGANDS; MELANOMA; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANS-ACTIVATORS; WNT2 PROTEIN; WOMEN;

EID: 3442894128     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1227     Document Type: Article

References (32)

1. Dann CE, Hsieh JC, Rattner A, et al. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature (Lond) 2001;412:86-90.
2. Hsieh JC, Rattner A, Smallwood PM, Nathans J. Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc Natl Acad Sci USA 1999;96:3546-51.
3. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59-88.
4. Uthoff SM, Eichenberger MR, McAuliffe TL, Hamilton CJ, Galandiuk S. Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Mol Carcinog 2001;31:56-62.
5. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science (Wash DC) 1998;281:1509-12.
6. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond) 1999;398:422-6.
7. Orford K, Orford CC, Byers SW. Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999;146:855-68.
8. Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000;13:15-24.
9. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50.
10. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60:1671-6.
11. Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 2001;152:87-96.
12. Ioannidis V, Beermann F, Clevers H, Held W. The beta-catenin-TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival. Nat Immunol 2001;2:691-7.
13. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003;5:367-77.
14. Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int J Oncol 2001;19:1003-7.
15. Roelink H, Wagenaar E, Nusse R. Amplification and proviral activation of several Wnt genes during progression and clonal variation of mouse mammary tumors. Oncogene 1992;7:487-92.
16. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994;54:2615-21.
17. Dale TC, Weber-Hall SJ, Smith K, et al. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 1996;56:4320-3.
18. Vider BZ, Zimber A, Chastre E, et al. Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene 1996;12:153-8.
19. Smith K, Bui TD, Poulsom R, et al. Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 1999;81:496-502.
20. Holcombe RF, Marsh JL, Waterman ML, et al. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 2002;55:220-6.
21. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 2003;56:280-5.
22. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
23. Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 2003;63:4547-51.
24. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-21.
25. van Gijn ME, Daemen MJ, Smits JF, Blankesteijn WM. The wnt-frizzled cascade in cardiovascular disease. Cardiovasc Res 2002;55:16-24.
26. Chai J, Du C, Wu JW, et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (Lond) 2000;406:855-62.
27. Srinivasula SM, Datta P, Fan XJ, et al. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem 2000;275:36152-7.
28. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (Lond) 1998;396:580-4.
29. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.
30. Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002;1:687-94.
31. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Investig Dermatol 1999;113:1076-81.
32. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002;5:65-72.